Equillium, Inc. (EQ): Price-to-Revenue Multiple
The GURU.Markets terminal provides the average P/S ratio for Equillium, Inc. (EQ), which has reached 28.50. This metric's trend smooths out market noise, testing the stability of capitalization relative to revenue. Risks for Equillium, Inc. (EQ) are linked to a dependence on partner payments and the potential failure of drug trials. The business is not subject to macro cycles, as demand for immunotherapy remains constant. Patent protection for antibodies and licenses in Asia guarantee stable royalties.
Metric breakdowns and analytics for Equillium, Inc. (EQ)
- current quotes and average value forecast:
- stock exchange capitalization data:
- book capitalization data:
- business debt structure and liquidity details:
- company profitability and valuation multiples indicators:
EQ - Net Income|Expected Net Income Equillium, Inc.|EQ - P/E Multiple|Market Cap to Projected Earnings equilliumbio.com|EQ - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Equillium Bio|EQ - Operating profit EBITDA|Net earnings per share for the last 12 months Equillium|EQ - Net earnings per share for the last 12 months|Year-over-year net earnings per share change for the last twelve months equilliumbio.com|EQ - Earnings growth in current year|Expected net earnings per share growth next year Equillium, Inc.
- issuer revenue and sales details:
General company analysis:EQ, Equillium Inc
Equillium, Inc. minimizes capital expenditures by outsourcing clinical trials to third-party contractors to concentrate resources on intellectual property. The P/S multiple relates current market capitalization to annual sales volume, determining the cost of each unit of revenue. This indicator allows an investor to verify the fairness of the asset's valuation, eliminating the risk of overpaying for inflated expectations. Analyzing the revenue multiple trend helps determine the optimal entry point into the asset.
Who Equillium, Inc. competes with
ARGX - Price to Sales|Price-to-Revenue Ratio BioNTech BNTX|Price-to-Revenue Multiple Abivax Pharma|ADMA: Market Cap to Revenue|PTGX - P/S Multiple|IMVT: P/S Multiple|KNSA - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Grifols|Price-to-Revenue Ratio ADPT|Price-to-Revenue Ratio Celldex (CLDX)|Price-to-Revenue Ratio AUPH (Aurinia Corp)|P/S Multiple BCRX (BioCryst)|Price-to-Revenue Coefficient veratx.com (VERA)|DNTH: Market Cap to Revenue|PHVS - P/S Multiple|AbCellera Biologics Inc (ABCL) - Price-to-Revenue Ratio|Market Cap to Revenue Tourmaline|Market Cap to Revenue PGEN|PHAR: Market Capitalization-to-Revenue Ratio|P/S Multiple NKTR|Price-to-Revenue Coefficient Upstream Bio, Inc.|Price-to-Revenue Ratio Zenas Biopharma, Inc. ZBIO|IMNM: Market Cap to Revenue Ratio|Gossamer Bio, Inc. - P/S Multiple|kalvista.com (KALV) - Market Cap to Revenue|SEPN (Septerna) - Market Cap to Revenue|PVLA - Price-to-Revenue Coefficient|SVRA (Savara Corp) - P/S Multiple|Price to Sales Rigel Corp RIGL|Price-to-Revenue Ratio AnaptysBio, Inc. (ANAB)|astriatx.com (ATXS) - Price-to-Revenue Multiple|Price-to-Revenue Ratio enGene ENGN|RAPT (RAPT Therapeutics Inc.) - Price-to-Sales Ratio|Aerovate - P/S Multiple|Market Capitalization-to-Revenue Ratio ACRS (Aclaris Therapeutics, Inc)|KYTX: P/S Multiple|tizianalifesciences.com (TLSA) - P/S Multiple|Price-to-Revenue Ratio Cabaletta Bio|VTYX: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Theratechnologies Inc (THTX)|Market Cap to Revenue Avalo Therapeutics Inc AVTX|P/S Multiple ELDN (Eledon Pharmaceuticals)|P/S Multiple agenusbio.com AGEN|CLYM: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ZURA (Zura Bio Ltd)|ATYR: P/S Multiple|ADAG - Price-to-Revenue Coefficient|Price-to-Revenue Ratio ImageneBio|Market Cap to Revenue Shattuck Therapeutics (STTK)|Price-to-Revenue Ratio Connect Biopharma (CNTB)|Market Cap to Revenue immunic-therapeutics.com IMUX|Atara Bio - Market Cap to Revenue|P/S Multiple InflaRx NV IFRX|XFOR - Price-to-Revenue Ratio|ACET (Adicet Bio) - Market Cap to Revenue Ratio|CELU: P/S Multiple|Price to Sales INmune Bio Inc (INMB)|BRNS (Barinthus Bio) - P/S Multiple|Price to Sales Kezar Life Sciences Inc KZR|Price-to-Revenue Ratio SAB Biotherapeutics (SABS)|akaritx.com (AKTX) - Price-to-Revenue Multiple|Enlivex Therapeutics Ltd. - Market Cap to Revenue|P/S Multiple Q32 Bio Inc QTTB|GeoVax Labs Inc - P/S Multiple|Price-to-Revenue Coefficient Edesa Biotech Corp EDSA|iBio, Inc. (IBIO) - Price-to-Revenue Ratio|CARM (Carisma Therapeutics Inc.) - Price-to-Revenue Ratio|Price-to-Revenue Ratio XTL Biopharmaceuticals Ltd.|Price-to-Revenue Ratio BOLT|P/S Multiple HCWB|Price-to-Revenue Coefficient aptevotherapeutics.com|AIM ImmunoTech Inc. - Market Cap to Revenue|P/S Multiple Aditxt Inc. ADTX|GRI - Price-to-Revenue Ratio|XORTX Therapeutics Inc (XRTX) - Market Cap to Revenue|HIND (ReShape Lifesciences) - Market Cap to Revenue|Revelation Biosciences Corp - Market Capitalization-to-Revenue Ratio|INDP (Indaptus Therapeutics) - P/S Multiple|scinai.com (SCNI) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio CalciMedica, Inc. (CALI)|affimed.com - Market Cap to Revenue Ratio|P/S Multiple ALLK (Allakos)|HOOK - Market Cap to Revenue|IGMS: Market Cap to Revenue|Price-to-Revenue Coefficient iteostherapeutics.com ITOS|OCEA: P/S Multiple|Price to Sales TC BioPharm (Holdings) Plc (TCBP)|Price-to-Revenue Ratio Third Harmonic Bio, Inc
